For a better future SCM Lifescience will do its best
SCM LifeScience unveils Phase 1·2a results of 'Acute Pancreatitis Stem Cell Material' at IPBM





SCM LifeScience's Phase 1 and Phase 2a clinical trials in acute pancreatitis were presented at the prestigious International Pancreatobiliary Meeting (IPBM) 2024, hosted by the Korean Pancreatobiliary Association.

IPBM 2024, held at Grand Walkerhill Seoul on April 5 and 6, is Korea's largest professional international academic conference in the pancreas and biliary tract sector. The event features lectures on a variety of practical topics, such as pancreas, biliary tract, tumors, and EUS new medical treatments, alongside presentations showcasing the latest medical technologies and insights. In particular, this year's conference was held in collaboration with the European Pancreatic Club (EPC), the European pancreatic association.

During the event, Professor Shin Il Sang from Soon Chun Hyang University Hospital Bucheon delivered a presentation entitled 'New Emerging Medical Treatment Using Mesenchymal Stem Cells.'

Shin is a member of the research team involved in the phase 1 and 2a clinical trials of SCM LifeScience's acute pancreatitis stem cell therapy, 'SCM-AGH'. In his presentation, Shin elucidated the background of mesenchymal stem cell treatment, the objectives and outcomes of the clinical trial, and proposed strategies to address the anticipated benefits and limitations of future stem cell treatments.

Attendees were particularly intrigued by the publication of phase 1 and 2a clinical trials in the prestigious journal Gastroenterology, underscoring its global impact. Moreover, it marked the world's first 'First-in-Human' study targeting patients with acute pancreatitis. The session witnessed active engagement with questions regarding the manufacturing process, dosage, and timing of administration of ‘SCM-AGH’.

"In 2011, we presented the world’s first research findings on the effectiveness of stem cells in treating acute pancreatitis in animal models in Gastroenterology," an official from SCM LifeScience said. "The publication in the renowned journal Gastroenterology (IF 33.8), following rigorous non-clinical investigations, holds profound significance. It served to elucidate the potential of stem cell therapy as a fundamental treatment for acute pancreatitis, providing insights to both Korean and international experts at this conference."

"We will continue to refine the therapy, ensuring it evolves into a trusted treatment option for patients and healthcare practitioners alike," the official further added.